Get the Stockscreener App
3.42
2.01%
-0.07
After Hours:
3.54
0.12
+3.51%
Agenus Inc stock is traded at $3.42, with a volume of 247.93K.
It is down -2.01% in the last 24 hours and down -23.32% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$3.49
Open:
$3.52
24h Volume:
247.93K
Relative Volume:
0.55
Market Cap:
$80.75M
Revenue:
$156.31M
Net Income/Loss:
$-245.76M
P/E Ratio:
-4.0235
EPS:
-0.85
Net Cash Flow:
$-234.16M
1W Performance:
+2.40%
1M Performance:
-23.32%
6M Performance:
-77.25%
1Y Performance:
-75.59%
1-Day Range:
$3.30
$3.60
1-Week Range:
$3.30
$4.06
52-Week Range:
$2.50
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.42 | 80.75M | 156.31M | -245.76M | -234.16M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
H.C. Wainwright reiterates Neutral on Agenus stock, focus on bot/bal in colorectal cancer - Investing.com
HC Wainwright Reaffirms "Neutral" Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Agenus secures $22 million mortgage, plans cost cuts By Investing.com - Investing.com Canada
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development - Yahoo Finance
Agenus Secures $22M Mortgage to Advance Cancer Treatment - TipRanks
Agenus secures $22 million mortgage, plans cost cuts - Investing.com
Agenus Secures $22M Mortgage, Plans 60% Cost Cut in Strategic Realignment | AGEN Stock News - StockTitan
Shareholders that lost money on Agenus Inc.(AGEN) should contact - GuruFocus.com
Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - GuruFocus.com
Agenus Inc. Sued for Securities Law ViolationsInvestors Shoul - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
What is B. Riley's Forecast for Agenus FY2024 Earnings? - MarketBeat
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Agenus stock hits 52-week low at $2.56 amid market challenges - Investing.com Australia
Agenus Chooses Flex Databases for Enhanced Pharmacovigilance Solutions - openPR
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Short Interest Update - MarketBeat
William Blair Weighs in on Agenus' Q4 Earnings (NASDAQ:AGEN) - MarketBeat
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround - Yahoo Finance
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
Biotech Brass Misled Investors About Cancer Drugs, Suit Says - Law360
Agenus Top Brass Sued Over FDA Response to Cancer Drug Trial - Bloomberg Law
Agenus Inc. (NASDAQ:AGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Q3 2024 Agenus Inc Earnings Call - Cbainfo
Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... - Yahoo Finance
Agenus Inc. Reports Progress in Immunotherapy Development - TipRanks
Agenus: Q3 Earnings Snapshot - Houston Chronicle
Agenus Reports Third Quarter 2024 Financial Results - citybiz
Agenus (AGEN) Q3 2024 Earnings Call Transcript - AOL
Agenus reports Q3 EPS ($3.08) vs ($3.29) last year - TipRanks
HC Wainwright Issues Pessimistic Forecast for Agenus (NASDAQ:AGEN) Stock Price - MarketBeat
Agenus Inc (AGEN) Q3 2024 Earnings: EPS Miss, Revenue at $25.1M vs. $61.48M Estimate - GuruFocus.com
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development - Business Wire
Earnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 Result - GuruFocus.com
Agenus stock hits 52-week low at $3.82 amid market challenges - Investing.com India
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 - Business Wire
Agenus to Showcase Breakthrough Cancer Immunotherapy Data at SITC 2024 Meeting | AGEN Stock News - StockTitan
Agenus (AGEN) Set to Announce Earnings on Tuesday - MarketBeat
AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Invest - GuruFocus.com
Agenus announces director Wiinberg's resignation and advisory role - Investing.com
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
FINAL AGEN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Agenus Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class ActionAGEN - PR Newswire
Class Action Filed Against Agenus Inc. (AGEN)November 5, 2024 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Malaysian Reserve
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):